Human IGFBP-4 Antibody

Catalog #: MAB8041
2 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB8041
MAB8041-SP

IGFBP‑4 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑4 Antibody.

1 Image

All IGFBP-4 Antibodies

Product Details

Citations (2)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IGFBP-4 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IGFBP-4 in ELISAs and Western blots.

Source

Monoclonal Mouse IgG₁ Clone # 82314

Purification

Protein A or G purified from ascites

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGFBP‑4
Asp22-Glu258
Accession # AAA62670

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human IGFBP‑4 (Catalog # 804-GB)

Human IGFBP-4 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human IGFBP‑4 Biotinylated Antibody (Catalog # BAF804)

Standard: Recombinant Human IGFBP-4 Protein, CF (Catalog # 804-GB)

Neutralization

Measured by its ability to neutralize IGFBP‑4 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND₅₀) is typically 20‑80 µg/mL in the presence of 0.3 µg/mL Recombinant Human IGFBP‑4 and 14 ng/mL Recombinant Human IGF‑II.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IGFBP‑4 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑4 Antibody. Recombinant Human IGFBP-4 (Catalog # 804-GB) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP-4 Monoclonal Antibody (Catalog # MAB8041). The ND₅₀ is typically 20-80 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-4

Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) residue precursor protein with a predicted 21 aa residue signal peptide that is processed to generate the 237 aa residue mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% amino acid sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, 4, -5, -6), and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.

References

Jones, J.I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.

Long Name

Insulin-like Growth Factor Binding Protein 4

Entrez Gene IDs

3487 (Human); 16010 (Mouse)

Alternate Names

BP-4; HT29-IGFBP; IBP4insulin-like growth factor-binding protein 4; IGF-binding protein 4; IGFBP4; IGFBP-4; IGFBP-4IBP-4; insulin-like growth factor binding protein 4

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human IGFBP-4 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by: